References
- Sephton-Smith R. Iron excretion in thalassemia major after administration of chelating agents. Br Med J 1962; 2: 1577–1580
- Graziano JH, Markerson A, Miller D R., et al. Chelation therapy in B-thalassemia major. Intravenous and subcutaneous deferoxamine. J Pediatr 1978; 92: 648–652
- Modell B. Advances in the use of iron-chelating agents for the treatment of iron overload. Prog Hematol 1979; 11: 267–312
- Estrov Z, Awas A, Wang Xin-Hua, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987; 69: 757–761
- Goodman LS, Gilman A. The Pharmaceutical Basis of Therapeutics, 6th ed, A. G. Gilman, L. S. Goodman, A. Gilman. McMillan, New York 1980; 16: 33–34, 1980
- Batley R, Scott J, Jain S, Sherlock S. Acute renal insufficiency occurring during intravenous deferoxamine therapy. Scand J Haematol 1979; 22: 277–279
- Bloomfield SL, Markerson AL, Miller, DR, Peterson CM. Lens opacities in thalassemia. J Pediatr Ophthalmol Strabismus 1978; 15: 154–156
- Davis SC, Marcu RE, Hungerford JL, et al. Ocular toxicity of high-dose intravenous deferoxamine. Lancet 1983; ii: 181–184
- Lakhaupal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary pigmentation and preferred optic neuropathy. Opthalmology 1984; 91: 443–451
- Rubinstein M, Dupont P, Doppee JP, Dehon C, Docubo J, Halnaut J. Ocular toxicity of deferoxamine. Lancet 1983; ii: 512–513
- Blake, Dr, Winyard P, Lunecf J, et al. Cerebral and ocular toxicity induced by deferoxamine. J Med 1985; 345–355
- Orton RB, de Veber LL, Sulh H MB. Ocular and auditory toxicity of long-term high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol 1985; 20(4)153–156
- Bourneris F, Monnier N, Dufier JL, Reveillaud RJ. toxicite oculaire severe de la deferoxamine chez l'hemodialyse. Nephrolgie 1987; 8: 27–29
- Borgna-Pignatti C, De Stefano P, Broglia AM. Visual loss in patient on high-dose subcutaneous deferoxamine. Lancet 1984; i: 681
- Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314: 869–873
- Black, Dr, Hall ND, Bacon PA, Dieppe PA, Halliwell B, Gutteridge J MC. Effects of a specific iron-chelating agents on animal models of inflammation. Am Rheum Dis 1983; 42: 89–93
- Fliester SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 1983; 22: 79–131
- Lederman HM, Cohen A, Lee J WW, Freedman MH, Gelfand WE. Deferoxamine: A reversible S-phase inhibitor of human lymphocytes proliferation. Blood 1984; 64: 748–753
- Kaplinsky C, Estrov Z, Freedman MH, Gelfand EW, Cohen A. Effect of deferoxamine in DNA synthesis, DNA repair, cell proliferation and differentiation of HL-60 cells. Leukemia 1987; 1: 437–441
- Ridgway E, Jaffee N, Watton DS. Leukemic ophthalmopathy in children. Cancer 1976; 38: 1744–1749
- Ha K, Kanaya S, Ikeda T, Ushio T, Nalcao Y, Yabuchi H. Cortical blindness in a child with acute leukemia. Acta Pediatr Scand 1980; 69: 781–782
- Patchell RA, White CL, Clark AW, Beschormer WE, Sautes GW. Neurologic complications of bone marrow transplantation. Neurology 1985; 35: 300–306